Reduced-dose bevacizumab vs. standard-dose bevacizumab in recurrent high-grade glioma: Which one is better? A meta-analysis
Reduced-dose bevacizumab vs. standard-dose bevacizumab in recurrent high-grade glioma: Which one is better? A meta-analysis
复制标题
DOI：
10.1016/j.clineuro.2020.106239
复制
发表时间：
--
期刊：
影响因子：
--
通讯作者：
Du Shasha
中科院分区：
文献类型：
--
作者：
Chen Yulei;Guo Longbin;Li Xuanzi;Liu Rongping;Ren Chen;Du Shasha
